Ascentage Pharma Group International 6855
HKEX · Hong Kong SAR China · Health Technology
HKD 30.74+0.38 (+1.25%)
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company’s management will participate in four upcoming investor conferences in New York, New York. Citi’s 2026 Biopharm
Half year earnings put Ascentage Pharma Group International (SEHK:6855) losses in focus Ascentage Pharma Group International (SEHK:6855) released half year earnings to June 30, 2026, reporting sales of CNY 302.21 million and a net loss of CNY 816.69 million, with a basic loss per share of CNY 2.19. Ascentage Pharma Group International’s recent half year results arrived alongside a sharp move in the stock, with a 1 day share price return of 12.08% and a 7 day share price return of 9.88% at...
Moby summary of ASCENTAGE PHARMA GROUP INTERNATIONAL's Q2 2026 earnings call
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.